Li Ying, Lu Zhongyang, Keogh Christine L, Yu Shan P, Wei Ling
Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, South Carolina 29425, USA.
J Cereb Blood Flow Metab. 2007 May;27(5):1043-54. doi: 10.1038/sj.jcbfm.9600417. Epub 2006 Nov 1.
Restoration of local blood supply in the post-ischemic brain plays a critical role in tissue repair and functional recovery. The present investigation explored beneficial effects of recombinant human erythropoietin (rhEPO) on vascular endothelial cell survival, angiogenesis, and restoration of local cerebral blood flow (LCBF) after permanent focal cerebral ischemia in adult mice. Saline or rhEPO (5,000 U/kg, intraperitoneal) was administered 30 mins before ischemia and once daily after ischemic stroke. Immunohistochemistry showed an enhancing effect of rhEPO on expression of EPO receptor (EPOR) of endothelial cells in the penumbra region 3 to 21 days after the ischemic insult. The treatment with rhEPO decreased ischemia-induced cell death and infarct volume 3 days after stroke. Specifically, rhEPO reduced the number of terminal deoxynucleotidyl transferase biotin-dUPT nick end labeling- and caspase-3-positive endothelial cells in the penumbra region. Colocalization of the vessel marker glucose transporter-1 (Glut-1) and cell proliferation marker 5-bromo-2'-deoxyuridine indicated enhanced angiogenic activity in rhEPO-treated mice 7 to 21 days after stroke. Western blot showed upregulation of the expression of angiogenic factors Tie-2, Angiopoietin-2, and vascular endothelial growth factor in rhEPO-treated animals. Local cerebral blood flow was measured by laser scanning imaging 3 to 21 days after stroke. At 14 days, LCBF in the penumbra was recovered to preischemia levels in rhEPO-treated mice but not in control mice. Our data suggest that rhEPO treatment upregulates the EPOR level in vascular endothelial cells, confers neurovascular protection, and enhances angiogenesis. We further show a promoting effect of rhEPO on LCBF recovery in the ischemic brain. These rhEPO-induced effects may contribute to therapeutic benefits in the treatment of ischemic stroke.
缺血后脑局部血液供应的恢复在组织修复和功能恢复中起着关键作用。本研究探讨了重组人促红细胞生成素(rhEPO)对成年小鼠永久性局灶性脑缺血后血管内皮细胞存活、血管生成及局部脑血流量(LCBF)恢复的有益作用。在缺血前30分钟腹腔注射生理盐水或rhEPO(5000 U/kg),缺血性卒中后每天注射一次。免疫组织化学显示,rhEPO对缺血损伤后3至21天半暗带区域内皮细胞的促红细胞生成素受体(EPOR)表达有增强作用。rhEPO治疗可减少卒中后3天缺血诱导的细胞死亡和梗死体积。具体而言,rhEPO减少了半暗带区域末端脱氧核苷酸转移酶生物素-dUTP缺口末端标记和半胱天冬酶-3阳性内皮细胞的数量。血管标志物葡萄糖转运蛋白-1(Glut-1)与细胞增殖标志物5-溴-2'-脱氧尿苷的共定位表明,rhEPO治疗的小鼠在卒中后7至21天血管生成活性增强。蛋白质印迹法显示,rhEPO治疗的动物中血管生成因子Tie-2、血管生成素-2和血管内皮生长因子的表达上调。在卒中后3至21天通过激光扫描成像测量局部脑血流量。在第14天,rhEPO治疗的小鼠半暗带区域的LCBF恢复到缺血前水平,而对照小鼠则未恢复。我们的数据表明,rhEPO治疗可上调血管内皮细胞中的EPOR水平,赋予神经血管保护作用,并增强血管生成。我们进一步证明了rhEPO对缺血性脑内LCBF恢复的促进作用。这些rhEPO诱导的效应可能有助于缺血性卒中治疗的有益效果。